DC-S239
DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC50 value of 4.59 μM. DC-S239 also displays selectivity for DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a. DC-S239 has anticancer activity[1].
Product Specifications
CAS Number
303141-21-1
UNSPSC
12352005
Target
Histone Methyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dc-s239.html
Purity
99.73
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(OCC)C1=C(SC(C(NC2=CC=CC([N+]([O-])=O)=C2)=O)=C1C)N
Molecular Formula
C15H15N3O5S
Molecular Weight
349.36
References & Citations
[1]Fanwang Meng, et al. Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening. J Med Chem. 2015 Oct 22;58 (20) :8166-81.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
DOT1L; EHMT2/G9a/KMT1C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC401856 20 µg
Nuclear Factor Erythroid Derived 2 (NFE2) (NM_006163) Human Over-expression Lysate
Sign In for Pricing
View Details 
LY431866 100 µg
ZADH1 (PTGR2) (NM_001146154) Human Over-expression Lysate
Sign In for Pricing
View Details 
